Asian Pacific Journal of Allergy and Immunology

  • HOME
  • ABOUT
  • EDITORS
  • SUBMISSION
    • Online Submission
    • Author Instructions
  • ISSUE
    • Current
    • Early Online
    • Archives
  • PERMISSIONS
  • CONTACT
  • ADVERTISE
Home
 / 
Original Article
 / 
Clinical trials of Cry j 1 and Cry j 2 T-cell epitope peptide-expressing rice in patients with Japanese cedar pollinosis

September 18, 2019
Original Article

Clinical trials of Cry j 1 and Cry j 2 T-cell epitope peptide-expressing rice in patients with Japanese cedar pollinosis

Shoji Hashimoto,1 Masatoshi Kawata,1 Nobusuke Mino,2 Satoshi Ogino,3 Noriaki Takeda,4 Kayoko Kawashima,5 Hidenori Takagi,6 Yuhya Wakasa,6 Makoto Takano,6 Masaki Tanaka,7 Yuji Tohda,8 Toshio Tanaka9

1 Department of Clinical Laboratory, Osaka Prefectural Hospital Organization Osaka Habikino Medical Center, Osaka, Japan
2 Secretariat, Osaka Prefectural Hospital Organization Osaka Habikino Medical Center, Osaka, Japan
3 Osaka Health Care and Allergy Support Organization, Osaka, Japan
4 Department of Otolaryngology, University of Tokushima School of Medicine, Tokushima, Japan
5 Department of Otorhinolaryngology, Osaka Prefectural Hospital Organization Osaka Habikino Medical Center, Osaka, Japan
6 Institute of Agrobiological Sciences, National Agriculture and Food Research Organization, Ibaraki, Japan
7 Masaki Clinic, Osaka, Japan
8 Department of Respiratory Medicine and Allergology, Kinki University, Osaka, Japan

Abstract

Background: In allergic models, administration of rice that expresses a hybrid peptide consisting of 7 major T cell epitopes of Cry j 1 and Cry j 2 (7Crp), suppressed allergic symptoms, IgE elevation and specific T cell response to Japanese cedar pollen.
Objectives: To evaluate the efficacy and safety of 7Crp-expressing rice in patients with Japanese cedar pollinosis.
Methods: A 24-week randomized, double-blind, placebo-controlled study was performed to see the efficacy of 7Crp on allergic symptoms using scoring systems, in which 45 patients were assigned to take either 5 g, 20 g test rice, or placebo daily. A 96-week open study was also conducted to determine its inhibitory effect on serum IgE and T cell proliferative response for Japanese cedar pollen, in which 10 patients consumed 5 g test rice daily.
Results: No adverse events associated with the test rice occurred, and the intake rate was more than 96%. The test rice did not show suppression of symptoms related to Japanese cedar pollinosis within 24 weeks. However, intake of 5 g test rice led to a significant decrease in T cell response to Japanese cedar pollen during and after the second disperse season in a 96-week open trial, whereas the specific IgE titer remained unchanged.
Conclusion: Tolerability and safety of 7Crp-expressing rice was accepted. Daily intake of up to 20 g transgenic rice did not provide beneficial effects on Japanese cedar pollinosis within 24 weeks, however, continuous intake of 5 g rice might reduce allergen specific T cell response.
Key words: Cry j 1 and Cry j 2, genetically modified rice, Japanese cedar pollinosis, oral allergen immunotherapy, T cell epitope peptide,

Full Text
Vol. 40, No. 4
Cry j 1 and Cry j 2, genetically modified rice, Japanese cedar pollinosis, oral allergen immunotherapy, T cell epitope peptide

Categories

  • Announcement (1)
  • Case Report (23)
  • Early Online (93)
  • Original Article (223)
  • Review Article (29)

Key words

allergen Allergic rhinitis Allergy Anaphylaxis Asthma atopic dermatitis child Children Chlorhexidine chronic rhinosinusitis chronic spontaneous urticaria Chronic Urticaria COVID-19 cytokine depression diagnosis drug allergy Drug hypersensitivity efficacy Epidemiology food allergy Food hypersensitivity house dust mite IgE Immunotherapy obstructive sleep apnea Omalizumab prevalence primary immunodeficiency Quality of life Questionnaire Reliability risk factor risk factors safety SARS-CoV-2 Sensitization Severe asthma Skin prick test Specific IgE Thai treatment urticaria vaccine Vitamin D
Asian Pacific Journal of Allergy and Immunology

Support Contact

Managing Editor
Ms. Patrawadee Pitakpolrat
E-mail: managingeditor@apjai-journal.org

Production Editor
Ms. Chanita Jangsawang
E-mail: chanita.j@apjai-journal.org

Asian Pacific Journal of Allergy and Immunology © 2025 All rights reserved.
All rights reserved | Privacy Policy